Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cabergoline for the Treatment of Chronic Pain Due to Endometriosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03928288
Recruitment Status : Not yet recruiting
First Posted : April 26, 2019
Last Update Posted : August 16, 2019
Sponsor:
Collaborator:
Brigham and Women's Hospital
Information provided by (Responsible Party):
Amy DiVasta, Boston Children’s Hospital

Brief Summary:
Endometriosis is dependent on angiogenesis (the sprouting of new blood vessels) for its growth and maintenance, but the side effects of currently approved angiogenesis inhibitors make these agents inappropriate for use in reproductive-age patients. This obstacle will be overcome by performing a randomized, double blind clinical trial aimed at repurposing an existing drug, cabergoline, as a safe, alternative angiogenesis inhibitor for adolescents and young women with endometriosis. This trial proposes a novel, non-hormonal, non-surgical therapeutic approach aimed at alleviating the pain and suffering associated with this common chronic disease that currently has limited treatment options.

Condition or disease Intervention/treatment Phase
Endometriosis Drug: Cabergoline 0.5 MG Drug: Placebo - Cap Phase 2

Detailed Description:

Endometriosis is a gynecologic condition in which tissue similar to the inside lining of the uterus (the endometrium) grows in locations in the body outside of the uterus. This abnormal growth can cause severe pain, often coinciding with a woman's menstrual period. Endometriosis affects about 10% of all women of reproductive age in the US, and leads to an estimated $22 billion/year in health care costs in the US alone. Endometriosis is a chronic disease that can progress over time, leading to infertility, debilitating pelvic pain, and resulting poor quality of life. Disease management involves not only prompt initiation of therapy, but also the maintenance of therapy for a prolonged length of time. As no cure currently exists, the disease typically progresses until menopause. Current medical management typically consists of hormonal medications and surgery, but these therapies are limited by lack of successful relief of symptoms, cost, or side effects. Many patients have endometriosis pain that is refractory to all available treatments. Safe, well-tolerated, long-duration additions to currently available treatments are sorely needed to ameliorate the chronic course of this disease.

Angiogenesis refers to the generation of new blood vessels from existing vessels. It is required for the growth of new living tissue and has been implicated in the initiation, maintenance, and spread of endometriosis. The investigators hypothesize that medications that inhibit the process of angiogenesis can be used to treat endometriosis. The angiogenesis inhibitor medications that are currently available cause severe side effects such as birth defects that prevent them from being safely used for treating endometriosis in young, otherwise healthy women. In contrast, there is an alternative medication, cabergoline, which has been extensively used in clinical practice for treatment of other endocrine conditions suffered by reproductive-aged women. While cabergoline appears to inhibit angiogenesis, it acts on this process indirectly such that it has very few side effects, making it appropriate for use in young women with endometriosis.

The investigators will conduct a clinical drug trial to determine whether cabergoline is an effective addition to standard hormonal therapy for decreasing persistent pelvic pain suffered by adolescents and young women with surgically-proven endometriosis. Patients who are interested in participating in our study will be randomized (decided by a flip of a coin) to either receive cabergoline, the investigational medication, or a placebo pill (a sugar pill). It is believed that after 6 months, patients who take cabergoline twice a week will demonstrate decreased pain scores and improved quality of life/ability to perform daily activities as compared to patients who take a placebo pill (sugar pill) twice weekly. During the research study, the investigators will study how pain symptoms, menstrual bleeding, levels of inflammation, risk for future cardiac disease, and measures of pain sensitivity change over time by using well-established, validated tools and techniques that the research team has utilized successfully in previous work.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Novel, Non-Hormonal Therapy for the Treatment of Chronic Pain Due to Endometriosis in Adolescent and Adult Women
Estimated Study Start Date : September 2019
Estimated Primary Completion Date : February 2023
Estimated Study Completion Date : February 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intervention
Cabergoline 0.5 mg PO twice weekly for 6 months
Drug: Cabergoline 0.5 MG
Medication
Other Name: Dostinex

Placebo Comparator: Placebo
Placebo capsule PO twice weekly for 6 months
Drug: Placebo - Cap
Placebo capsule




Primary Outcome Measures :
  1. Change in pain assessed by the Brief Pain Inventory Interference Scale (BPI) over 6 months [ Time Frame: every 6 weeks for 6 months ]
    BPI: A 7-item self-report measure. The items in this scale can be grouped into those that assess physical functioning (general activity; walking ability; normal work, including both work outside the home and housework), those that assess emotional functioning (mood; relations with people; enjoyment of life), and a single item that assesses the extent to which pain interferes with sleep. Either the item asking about the "worst pain" or the arithmetic mean of the four severity items can be used as measures of pain severity; the arithmetic mean of the seven interference items can be used as a measure of pain interference. The BPI is anchored between a scale of zero (no pain/interference) to ten (maximum pain/interference). The magnitude of treatment-associated change in BPI Interference Scale scores in open-label and randomized clinical trials ranges from 1 to 3 points, depending on the specific pain conditions and treatments studied.

  2. Change in pain severity measured by Visual Analog Scale (VAS) over 6 months [ Time Frame: every 6 weeks for 6 months ]
    VAS: A measurement of pain intensity, assessed by a 0 to 10 numerical rating scale, to rate maximum and average pain intensity over the preceding 7 days. Higher scores indicate more severe pain intensity.

  3. Change in pain measured by Biberoglu and Behrman patient ratings scale (B&B pain scale) over 6 months [ Time Frame: every 6 weeks for 6 months ]
    Biberoglu and Behrman patient ratings scale (B&B pain scale): Survey that assesses dyspareunia, dysmenorrhea, and noncyclic pelvic pain. Each is graded on a scale from 0 to 3 (or 4), with higher numbers indicating more severe symptoms.


Secondary Outcome Measures :
  1. Change in measurements of serum biomarkers of angiogenesis and inflammation over 6 months [ Time Frame: every 3 months for 6 months ]
    Measurement of serum concentrations of high sensitivity C-reactive protein, interleukins 1B and 8, tumor necrosis factor alpha, and vascular endothelial growth factor

  2. Change in cardiovascular dysfunction measured by pulse wave velocity over 6 months [ Time Frame: baseline and 6 months ]
    Peripheral wave velocity is an ultrasound measurement of the rate at which pressure waves move down a blood vessel. It is collected by using two pressure catheters placed a known distance from one another, the "Pulse Wave Distance".

  3. Change in measures of central hypersensitization measured by quantitative sensory testing at 6 months [ Time Frame: every 3 months for 6 months ]
    Quantitative sensory testing (QST) is a single, standardized protocolized test that involves measurement of 3 pain threshold tests (cutaneous dynamic brush allodynia, muscular pain threshold, temporal summation test) that will be measured at the abdomen

  4. Incidence of vaginal bleeding over 6 months [ Time Frame: completed daily for 6 months ]
    Measurement of the incidence of vaginal bleeding using phone-based survey to document the presence/absence of vaginal bleeding



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years to 40 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female with surgically-confirmed endometriosis, determined at laparoscopy performed within 3y prior to study baseline
  • Age 15 years to 40 years
  • Current use ≥ 2 months duration of hormonal therapy such as combined oral contraceptives, norethindrone acetate, or levonorgestrel intrauterine device
  • Current pelvic pain (score ≥ 3 on Visual Analog Scale, where 0 represents absence of pain and 10 indicates unbearable pain) present for ≥ 14 days/month over the 2 months prior to study enrollment
  • Willingness to comply with visit schedule and protocol

Exclusion Criteria:

  • Pre-menarche or post-menopause
  • Contraindications to cabergoline (e.g., cardiac valve disorder; pulmonary, pericardial, retroperitoneal fibrotic disorder; hypersensitivity to ergot derivatives; uncontrolled hypertension)
  • Significant mental or chronic systemic illness that might confound pain assessment or the ability to complete the study
  • Pregnant, breastfeeding, or planning to become pregnant in the next 6 months
  • Impaired liver function (ALT > 2x normal) or liver disease
  • Breast cancer, current or previous
  • Thromboembolic disease, current or previous
  • Use of other drugs that affect dopamine (e.g., phenothiazines, metoclopramide, butyrophenones)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03928288


Contacts
Layout table for location contacts
Contact: Anna Kapral 617-355-2212 bce@childrens.harvard.edu
Contact: Laura Pavitt 617-355-3309 bce@childrens.harvard.edu

Locations
Layout table for location information
United States, Massachusetts
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Boston Children’s Hospital
Brigham and Women's Hospital

Layout table for additonal information
Responsible Party: Amy DiVasta, Associate Professor of Pediatrics, Boston Children’s Hospital
ClinicalTrials.gov Identifier: NCT03928288     History of Changes
Other Study ID Numbers: P00031528
First Posted: April 26, 2019    Key Record Dates
Last Update Posted: August 16, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Endometriosis
Chronic Pain
Pain
Neurologic Manifestations
Signs and Symptoms
Genital Diseases, Female
Cabergoline
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs